Abstract Number: 1357 • ACR Convergence 2022
The ANCA-Associated Vasculitis Patient-Reported Outcome (AAV-PRO) Captures Depression and Health-Related Quality of Life More Than Disease Activity and Damage
Background/Purpose: The ANCA-associated vasculitis patient-reported outcome (AAV-PRO) is a new disease-specific PRO developed to capture the impact of having AAV and dealing with its treatment…Abstract Number: 2070 • ACR Convergence 2022
Health-Related Quality of Life Across the Spectrum of Connective Tissue Diseases: A Latent Profile Analysis
Background/Purpose: Poor health-related quality of life (HR-QoL) is well recognised within patients with connective tissue diseases (CTD). We hypothesised that subgroups of patients across the…Abstract Number: 2089 • ACR Convergence 2022
The Implication of Skin Involvement on Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE) Patients
Background/Purpose: Skin involvement in Systemic Lupus Erythematosus (SLE) occurs in 50-85% of patients making it one of the most commonly affected organs in SLE. Previous…Abstract Number: 2090 • ACR Convergence 2022
Evaluation of Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) vs. SLEDAI-2K Glucocorticoids (SLEDAI-2KG) on Patient Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE)
Background/Purpose: Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Glucocorticoid Index (SLEDAI-2KG) is a novel valid index able to measure disease activity while accounting for prednisone…Abstract Number: 2243 • ACR Convergence 2022
Patient Reported Outcomes from a Randomized Phase 3 Trial of Sarilumab in Polymyalgia Rheumatica
Background/Purpose: Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic disease in the elderly. The phase 3 SAPHYR trial (NCT03600818) assessed the efficacy and safety of…Abstract Number: 0187 • ACR Convergence 2022
Patient-reported Outcomes and Quality of Life in Patients with Rheumatoid Arthritis Treated with GP2015: Final Results from a Real-world Study
Background/Purpose: COMPACT is a non-interventional study evaluating the persistence, effectiveness, safety and patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA), axial-spondyloarthritis or psoriatic arthritis…Abstract Number: 0199 • ACR Convergence 2022
Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes – 16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis
Background/Purpose: Izokibep is a unique IL-17A inhibitor with high potency and small molecular size designed to overcome the limitations of monoclonal antibodies. IL-17 is a…Abstract Number: 0237 • ACR Convergence 2021
Self-perceived General Health at Start of Anti-TNF Therapy Predicts Therapeutic Response in Patients with Rheumatoid Arthritis: Analysis from the Czech Biologics Registry ATTRA
Background/Purpose: SF-36 and its components, as well as other PROs have been shown to predict various disease outcomes. We hypothesized that positive responses to questions…Abstract Number: 0741 • ACR Convergence 2021
Assessing the Relationship of Patient Global Assessment of Disease Activity and Health Related Quality of Life by SF-36 with Other Patient-Reported Outcomes in Rheumatoid Arthritis: Post Hoc Analyses of Data from Phase 3 Trials of Baricitinib
Background/Purpose: Improvements in patient-reported outcomes (PROs) were demonstrated in randomized controlled trials (RCTs) of baricitinib (BARI), an oral Janus kinase (JAK)1/JAK2 inhibitor, for the treatment…Abstract Number: 0890 • ACR Convergence 2021
Depression Is Associated with Frailty in Systemic Lupus Erythematosus Patients: Multicenter Retrospective Analysis Using Systemic Lupus Erythematosus International Collaborating Clinics-Frailty Index
Background/Purpose: Systemic Lupus Erythematosus International Collaborating Clinics-Frailty Index (SLICC-FI) is a novel health measure in systemic lupus erythematosus (SLE) and was reported to have impact…Abstract Number: 1822 • ACR Convergence 2021
Relationships Between Dermatologic Symptoms and Health-related Quality of Life in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
Background/Purpose: Dermatologic symptoms of PsA can substantially impact patient (pt) health‑related quality of life (HRQoL);1 itch is the most commonly reported, and among the most…Abstract Number: 0025 • ACR Convergence 2020
Clinical and Psychological Assessment of Rheumatoid Arthritis Patients with Fibromyalgia: A Real World Study
Background/Purpose: To assess the clinical features and psychological status of the rheumatoid arthritis(RA) patients with fibromyalgia(FM) in a real-world observational setting.Methods: Between December 2018 to…Abstract Number: 0136 • ACR Convergence 2020
Filgotinib Significantly Improved Patient-reported Health-related Quality of Life for Patients with Active Rheumatoid Arthritis: A Post Hoc Analysis of SF-36 and HAQ-DI from Phase 3 Studies
Background/Purpose: Reduction in pain and fatigue, maintenance of physical functioning, and improvement in health-related quality of life (HRQoL) are vital aspects of successful treatment for…Abstract Number: 0353 • ACR Convergence 2020
Achievement of Sustained Remission and Low Disease Activity with Secukinumab Improves Quality of Life and Physical Function in Patients with Psoriatic Arthritis: Results from a Randomized Phase 3 Study
Background/Purpose: A treat-to-target approach in psoriatic arthritis (PsA) was recommended by EULAR and GRAPPA to achieve remission (REM) or low disease activity (LDA), by regular…Abstract Number: 1102 • ACR Convergence 2020
Neuropathic Pain in Inflammatory Hand Osteoarthritis(OA) Lowers Quality of Life and May Require Another Approach Than Anti-inflammatory Treatment
Background/Purpose: To investigate whether neuropathic pain is present in patients with inflammatory hand OA, to investigate characteristics of those patients and the impact of neuropathic…
ACR Meeting Abstracts